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Abstract
Despite new treatment options in lung cancer, there is still a need for better biomarkers to assist in therapy
decisions. Angiogenesis has been associated with tumour growth and dissemination, and the vascular prolifera-
tion index (VPI) is a valuable prognostic marker in other tumours. Nestin, a marker of immature endothelium,
was previously applied in combination with Ki67 for proliferating endothelium as a novel marker (Nestin-Ki67)
of ongoing angiogenesis. Here, the prevalence and prognostic impact of vascular proliferation on lung cancer-
specific survival (LCSS) in lung adenocarcinomas was studied. Selected tumour slides from a cohort of 210
patients treated surgically for adenocarcinoma at Haukeland University Hospital (Norway) from 1993 to 2010
were stained for Nestin-Ki67. VPI, the ratio between the density of proliferating vessels and the overall micro-
vessel density were used, and the cut-off value was set at 4.4% (upper quartile). High VPI was associated with
the presence of blood vessel invasion (p 5 0.007) and tumour necrosis (p 5 0.007). Further, high VPI was signif-
icantly associated with reduced LCSS (p 5 0.020). By multivariate analysis, VPI remained an independent prog-
nostic factor for reduced LCSS (HR 1.7; 95% CI 1.04–2.68; p 5 0.033) when adjusted for other prognostic
clinico-pathological features. In conclusion, microvessel proliferation assessed using the VPI was associated with
aggressive tumour features such as blood vessel invasion and tumour necrosis and, independently, decreased
LCSS. This marker should be further explored in separate cohorts, and in trials of anti-angiogenesis therapy.
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Introduction
The incidence of non-small cell lung carcinoma
(NSCLC) is still rising and, despite new and targeted
treatment strategies, the mortality rate is still high (5
year relative survival rate 14% for men and 21% for
women in Norway) [1]. Adenocarcinomas (AC) com-
prise around 40% of all new cases of lung cancer [2]
and, for this patient group, several new treatment
options such as EGFR mutations and EML-ALK
translocations have emerged during the past two dec-
ades based on molecular changes in tumour cells [3].
Lately, changes in the tumour microenvironment
have received attention, especially with the emer-
gence of immunotherapy [4].
Angiogenesis, i.e. the sprouting of new vessels
from existing vasculature, has long been considered a
hallmark of cancer [5,6], and a prerequisite for
tumours to grow beyond 1–2 mm in diameter and
spread [7]. For NSCLC, there are now FDA approved
anti-angiogenic drugs targeting the vascular endothe-
lial growth factor receptor system, with effects supe-
rior to non-angiogenic inhibitors according to a
recent review by Hong et al [8], and there are several
trials ongoing. There are, however, no predictive bio-
markers for selecting patients who might benefit
from such therapy [9].
Evaluation of tumour angiogenesis has been the
subject of several studies, with microvessel density
(MVD) regarded as an appropriate marker [10]. In
1991, MVD was first described to have an influence
on patient prognosis in breast cancer [11]. In
NSCLC, the first report was presented the following
year, describing higher MVD to indicate increased
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metastatic rate [12]. Since then, reports regarding the
prognostic benefits of counting vessels in NSCLC
have yielded somewhat conflicting results [13–16].
The predictive value of MVD for anti-angiogenic
treatment effect has also been debated [17,18], and
there have been discussions on the quantification
methods as well as use of antibodies to detect micro-
vessels [19–21].
Traditionally, MVD has been detected using factor
VIII, CD31, or CD34 [22,23]. Previous studies have
indicated that co-expression of factor VIII or CD34
with the proliferation marker Ki67 in endothelial
cells is a better marker for prognosis in breast, endo-
metrial, pancreatic, and prostate cancer [24–29]. For
NSCLC, there have been limited data supporting this
suggestion [30]. Notably, combining MVD with pro-
liferation markers into a vascular proliferation index
(VPI) provided better information on associations
with aggressive tumour features and patient prognosis
in several tumours [25,27,29]. Such information has
not been examined and presented for NSCLC.
Since factor VIII, CD31, or CD34 also stain pre-
existing vessels in solid organs, there have been
attempts to find markers for newly formed vessels,
such as vasohibin-1 [30,31]. Similarly, the intermedi-
ate filament protein Nestin has been promoted as a
marker of immature endothelium [32]. Nestin was
initially thought to be expressed in neuroepithelial
stem cells alone, but has since been found in several
other undifferentiated cells, including blood vessel
endothelium [33]. Using Nestin-Ki67 in dual immu-
nohistochemical staining of activated angiogenesis,
we previously reported that this novel angiogenesis
marker was more sensitive for prognostic impact
than standard MVD [24]. In lung cancer, Nestin
expression has been studied before, but mainly as a
tumour cell marker [34–38]. In addition, one single
study indicated that Nestin positive vessels correlated
with a higher tumour stage in NSCLC [39], although
no survival data were presented, and the frequency of
proliferating vessels was not assessed.
Here, we examined the presence and density of
microvascular proliferation using the novel angiogen-
esis marker Nestin-Ki67, in relation to patient prog-
nosis and clinico-pathological features in lung AC.
Materials and methods
Patients
Selected tissue blocks from 213 patients surgically
treated for lung AC from 1993 to 2010 at Haukeland
University Hospital, Bergen, Norway, were retrieved
from the archives of the Department of Pathology,
Haukeland University Hospital. Twenty-two of these
cases had matched surgical biopsies from metastatic
lesions, and these were also retrieved from the
archives. After immunohistochemical staining (details
below), 210 primary tumours and 19 matched meta-
static tumours had sufficient tissue to be included in
the study. There were 109 men (52%) and 101
women (48%) in the cohort, with a median age of 67
years (range 32–84). Of these AC, the most frequent
growth patterns were solid and acinar predominant
(38% each), followed by papillary and lepidic pre-
dominant (9% each), and five cases of mucinous ade-
nocarcinoma (2%); there were three cases of
micropapillary predominant pattern, and two cases of
minimally invasive adenocarcinoma (1% each).
Finally, 90% of patients were current or former
smokers.
Clinical data were obtained by reviewing hospital
records, and complete follow-up data for all 210
patients were collected by 16 May 2015 (median
follow-up of survivors was 81 months, range 1–222).
At latest follow-up, 93 patients (44%) were dead
because of lung cancer, 51 (24%) were dead from
other causes, 7 (3%) were alive with disease recur-
rence, and 59 patients (28%) were fully recovered.
The study was approved by a regional ethics com-
mittee (#2013–529 REK-Nord) prior to tissue collec-
tion and retrieval of patient data. The requirement for
informed consent was waived.
Tissue handling and immunohistochemistry
From the surgical specimens, initially submerged in
10% formalin for an average of 5.8 days, sections
from tumour tissue was paraffin embedded (an aver-
age of four blocks per tumour, range 1–16). Selected
sections from primary tumours and metastatic lesions
were stained by immunohistochemistry for Nestin-
Ki67. Briefly, 4 lm sections where deparaffinised in
xylene and rehydrated in alcohol and distilled water.
Target retrieval was obtained by boiling in buffered
solution at pH6 (Dako S1699) using a microwave
oven for 20 min. After cooling, distilled water was
added to reduce the fluid to room temperature. Slides
were then transferred to a humidifying chamber
(Magnetic Immuno Staining Tray, Cell Path, UK).
Dual Endogenous Enzyme Block (Dako 2003) was
added for 8 min to block endogenous peroxidase.
Buffered saline solution (Dako S3006) was used in
between steps. Incubation with primary antibody was
performed at room temperature for 30 min (Nestin
mouse IgG SC-23927, Santa Cruz Biotech 10c2, dilu-
tion 1:50 and Ki67 rabbit IgG Clone SP6, Thermo
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Sciences, dilution 1:100, both in diluent with back-
ground reducing components, Dako S0809). A HRP-
labelled polyclonal anti-mouse polymer (Dako 4007
for Nestin) and goat anti-rabbit IgG (H 1 L) alcalic-
phosphatase (Southern Biotech, Cat. No. 4050–04, for
Ki67) in the ratio Gar-AP:EnV-M 1:100 as secondary
antibody were added for 30 min at room temperature.
For visualization, the Ferangie Blue TM Chromogen
System (Biocare Medical) and AEC 1 Substrate
Chromogen (Dako K3469) were added sequentially
for 10 and 20 min, respectively, rinsing with distilled
water between steps. Slides were mounted using Fara-
mount mounting media (Dako S3025).
At evaluation, there were two cases with insuffi-
cient tumour tissue left for evaluation of intra-
tumoural vessels, and in one case the tissue was
destroyed during the staining procedure. Thus, 210
primary tumours and 19 matched metastatic lesions
were eligible for evaluation of microvessels.
Variables recorded
Clinico-pathological data
Histological type and grade were determined accord-
ing to World Health Organization criteria [40], and
cases with well to moderate differentiation were
merged into a low-grade group, whereas poorly dif-
ferentiated and undifferentiated tumours were merged
into a high-grade category [41,42]. The predominant
growth pattern in these AC was recorded according
to the International Association for the Study of
Lung Cancer [43]. Blood vessel invasion (BVI), lym-
phatic vessel involvement, pleural invasion, necrosis,
and tumour inflammation were recorded from routine
haematoxylin and eosin stained sections without the
use of additional staining as previously described
[44]. Briefly, necrosis was regarded as present when
areas of dead tumour cells were found (lower thresh-
old: clusters of at least 10 necrotic tumour cells).
Tumour stage was determined using the TNM Classi-
fication of Malignant Tumours (7th edition) [45].
Data on age at surgery, fixation time (in days),
tumour size (defined as largest diameter measured
macroscopically), time of disease recurrence, time of
death, cause of death, type of recurrence (local,
regional, distant), and sites of metastasis (liver, adre-
nals, brain, bone, skin, and others such as intra-
thoracic sites, distant lymph nodes, and kidneys)
were included from the clinical records.
Microvessel density/proliferating microvessel density
The MVD was recorded in accordance with the
method described by Weidner, with minor
modifications [24,46]. Sections stained with Nestin-
Ki67 were first scanned at low magnification (340
and 3100) to identify areas of the tumour with the
highest number of Nestin-positive vessels (red stain).
This ‘hot-spot’-area was indicated, and 10 non-
overlapping high power fields (HPF, 3400, field size
0.239 mm2) were examined sequentially for the total
number of positive vessels. Areas of necrosis and
fibrosis formation were avoided, and there had to be
at least 50% viable tumour cells in the HPF for it to
be examined. All stained vessels were counted, includ-
ing single endothelial cells. Lumen formation was not
mandatory for counting a vessel, but cells needed to
morphologically resemble endothelial cells or cell
clusters [11]. Elements with non-specific staining,
nerves, fibroblasts, and positive tumour cells were
excluded from these counts. The number of stained
vessels per square-millimetre was recorded as the
MVD.
The number of proliferating vessels proliferating
microvessel density (pMVD) was obtained from the
same ten HPF as MVD. A vessel positive for Nestin
that contained at least one Ki67-positive nucleus
(blue) within the endothelial cells, counted as a pro-
liferative vessel (Figure 1). The intensity of Ki67 in
endothelial nuclei was compared to the intensity in
tumour cell nuclei in each case (as an internal posi-
tive control). The number of proliferating vessels per
square-millimetre was recorded as the pMVD in each
case.
Vascular proliferation index
The VPI was obtained by dividing the number of
proliferating vessels by the microvessel density
(pMVD/MVD), and is presented as a percentage.
Figure 1. Nestin-Ki67 dual immunohistochemical staining
(3400). A nestin-positive (red) immature endothelial cell co-
expressing Ki67 (blue) in a proliferating vessel is indicated by
an arrow.
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Intra- and inter-observer agreement
All cases were scored twice by one experienced
pathologist (MR), blinded to clinical data. For MVD,
the Spearman correlation coefficient (rho) was 0.75
(p< 0.001), and the measure of intra-observer agree-
ment (Kappa) for cut-off values median and upper
quartiles were 0.58 and 0.54, respectively. Rho for
pMVD was 0.75 (p< 0.001), with Kappa 0.54 and
0.71 for median and upper quartile cut-off values. The
Spearman rho for VPI was 0.66 (p< 0.001), and the
Kappa values were 0.50 and 0.55, respectively.
We then performed an inter-observer variability test
in a subset of 25 randomly selected cases, and these
were counted independently by another researcher
(SA) with experience in counting microvessels by this
method. We found significant correlations between
counts, with Spearman’s correlation coefficient (rho)
being 0.61 for MVD (p 5 0.001), 0.56 for pMVD
(p 5 0.003), and 0.58 for VPI (p 5 0.002). Using the
upper quartile as cut-off gave Kappa values of 0.26
for MVD, 0.56 for pMVD, and 0.75 for VPI.
Cut-off values
For the vascular markers, cut-off values for dichoto-
mization were determined prior to statistical analyses
by exploring the frequency distribution. By default,
we examined median and quartile values. Number of
events across quartile subgroups was considered in
order to secure sufficient statistical power in survival
analyses. This is also in accordance with our previous
studies [27,29,47]. In the final analyses, associations
and survival studies were performed using the upper
quartile as cut-off value. We also performed survival
analyses using the median as cut-off value.
Statistical analyses
For associations between categorical data, Pearson
chi-square test was performed, and odds ratios were
computed by the Mantel–Haenzel method. Associa-
tions between continuous and categorical data were
analysed using the independent samples Mann–Whit-
ney U-test. Correlations between primary tumours
and metastatic lesions were analysed by the Wil-
coxon signed rank test, and frequency distributions
were analysed by the McNemar test for related sam-
ples. The Spearman correlation test was used to ana-
lyse intra- and inter-observer agreement of
continuous variables, and Cohen’s kappa for dicho-
tomized variables. Lung cancer-specific survival
(LCSS), recorded as time from surgery to the time of
death from lung cancer was regarded as the primary
end-point for survival analyses. Patients alive at last
follow-up or dead from other causes were censored.
For survival analysis, Kaplan-Meier curves were
computed and differences between groups were ana-
lysed using the log-rank test. Univariate survival
analyses were performed by the Cox’ proportional
hazards method. Assumptions of proportionality were
checked using log-log plots. For multivariate analyses
by the Cox’ proportional hazards method, variables
with P values 0.10 were included in the final
model (likelihood-ratio test for differences). Interac-
tions were tested by applying the product-term
method. Significance was set at P values less than
0.05. The statistical analyses were performed using
SPSS (IBM, versions 22–24).
Results
Median MVD/mm2 was 39.5 (mean 43.8, range 4.4–
149.8), median pMVD/mm2 was 0.9 (mean 1.2, range
0–7.9), and median VPI was 1.9% (mean 2.9%, range
0–21%). The interquartile range for MVD was 25.2–
59.5%, for pMVD 0–1.7%, and for VPI 0–4.4%.
These continuous variables were dichotomized using
the upper quartile limit (59.5, 1.7, and 4.4%, respec-
tively) as the cut-off value (see above).
Fixation time did not affect these results. When
correlating VPI with fixation time as a continuous
variable, no significance was found (p 5 0.73 by
Pearson correlation; Spearman’s rho 20.05,
p 5 0.47). Also, no significance was found comparing
pMVD and MVD with fixation time (data not
shown). No difference in mean VPI, pMVD, or
MVD was found when comparing cases above or
below the mean fixation time (data not shown).
Associations
Microvessel density
High MVD was associated with lower tumour stage
(OR 0.5; 95% CI 0.27–0.98; p 5 0.043), but not with
any of the other clinico-pathological factors.
Proliferating microvessel density
The number of proliferating vessels showed a signifi-
cant association with high tumour grade (correspond-
ing to poorly differentiated or undifferentiated
tumours versus well to moderately differentiated
tumours) (OR 2.0; 95% CI 1.11–3.76; p 5 0.022) and
presence of necrosis (OR 2.7; 95% CI 1.38–5.11;
p 5 0.003). No associations with other clinico-
pathological factors were found, including adenocar-
cinoma subtypes.
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Vascular proliferation index
The VPI was significantly associated with invasion
into blood vessels (OR 2.4; 95% CI 1.27–4.63;
p 5 0.007) and presence of tumour necrosis (OR 2.7;
95% CI 1.35–5.33; p 5 0.004), but not with other
clinico-pathological factors (Table 1). High VPI
showed a trend towards being associated with distant
metastasis as first site of recurrence (OR 2.4; 95% CI
0.90–5.59; p 5 0.089), compared to recurrence at a
local or regional site.
Survival analysis
A high VPI (by upper quartile) was significantly asso-
ciated with reduced LCSS (log-rank test, p 5 0.020),
with estimated median survival of 42 months com-
pared with low VPI of 135 months (Figure 2A). VPI
above the upper quartile level was also significantly
associated with shorter time to recurrence (log-rank
test, p 5 0.012) (Figure 2B). Neither MVD nor pMVD
above the upper quartile level were significantly asso-
ciated with survival. In addition, a high VPI and
pMVD (with median as cut-off value) were signifi-
cantly associated with reduced LCSS (p 5 0.020 and
p 5 0.005 by log-rank test), whereas MVD was not.
By univariate analysis, tumour grade, blood and
lymphatic vessel invasion, tumour necrosis, and
tumour stage were significantly associated with LCSS
(Table 2), whereas patient age and smoking history
were not significant. In a multivariate model where
clinico-pathological variables significant in univariate
analysis were included, VPI above the upper quartile
level remained an independent prognostic factor for
LCSS (HR 1.7; 95% CI 1.04–2.68; p 5 0.033), along
with lymph vessel invasion and tumour stage (Table
2). The proportional hazards assumption was tested
and met for all variables entered into the model.
Vascular proliferation in metastatic lesions
For the metastatic lesions, 19 cases with sufficient
tissue were left for analysis. In these, the median
MVD/mm2 was 16.6, median pMVD/mm2 was 0.9,
and median VPI 5.0%. The upper quartile values for
MVD/mm2, pMVD/mm2, and VPI were 29.3, 1.7,
and 9.5%, respectively.
The median MVD/mm2 was significantly higher in
primary tumours versus metastatic lesions (39.5 ver-
sus 17.1; p 5 0.001 by Wilcoxon signed rank test).
No significant differences were found for pMVD/
mm2 or VPI, comparing metastases with paired
Table 1. Demographic and clinico-pathological data with associations [by Pearson chi-square test and odds ratios (OR)] with VPI
(cut-off by upper quartile) (n 5 210)
VPI low VPI high
n (%) n (%) OR (95% CI) P
Age (median)
<67 75 (75.0) 25 (25.0) 1 ns
67 82 (74.5) 28 (25.5) 1.0 (0.55–1.91)
Sex
Male 77 (70.6) 32 (29.4) 1 ns
Female 80 (79.2) 21 (20.8) 0.6 (0.34–1.19)
Histological grade
Low 89 (79.5) 23 (20.5) 1 0.094
High 68 (69.4) 30 (30.6) 1.7 (0.91–3.20)
BVI
Absent 117 (80.1) 29 (19.9) 1 0.007
Present 40 (62.5) 24 (37.5) 2.4 (1.27–4.63)
LVI
Absent 116 (74.4) 40 (25.6) 1 ns
Present 41 (75.9) 13 (24.1) 0.9 (0.45–1.89)
Tumour necrosis
Absent 77 (84.6) 14 (15.4) 1 0.004
Present 80 (67.2) 39 (32.8) 2.7 (1.35–5.33)
Pleural invasion
Absent 107 (73.3) 39 (26.7) 1 ns
Present 50 (78.1) 14 (21.9) 0.8 (0.38–1.54)
Tumour stage
I 67 (76.1) 21 (23.9) 1 ns
II-IV 88 (74.6) 30 (25.4) 1.1 (0.57–2.07)
BVI, blood vessel invasion; LVI, lymphatic vessel involvement; VPI, vascular proliferation index (dichotomized by upper quartile); OR, odds ratio; CI, confidence
interval; P values from Pearson chi-square test; ns, non-significant (P value> 0.05).
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primary tumours. No association with sites of metas-
tasis was found (data not shown).
Nestin expression in tumour cells
Nestin positivity in tumour cells was found in 45
cases (21%) and was associated with high tumour
grade (OR 1.9; 95% CI 1.10–3.89; p 5 0.043), and
high tumour stage (OR 2.5; 95% CI 1.19–5.10;
p 5 0.014). Further, the solid predominant subtype of
AC had significantly higher frequency of Nestin posi-
tive tumour cells compared to acinar or other growth
patterns (p 5 0.005). Nestin was also associated with
lymph vessel invasion (OR 2.1; 95% CI 1.04–4.25;
p 5 0.037), whereas tumour cell expression of Nestin
was not related to LCSS.
Discussion
We present here a novel marker for evaluation of
active angiogenesis in lung adenocarcinoma by the
use of Nestin-Ki67 co-expression given as a VPI. We
found that high VPI was significantly associated with
aggressive tumour features such as BVI and presence
of tumour necrosis, and reduced cancer specific sur-
vival in lung AC.
Vascular proliferation has been proposed as a
marker of neoangiogenesis for other solid tumours
such as endometrial carcinoma [29], prostatic adeno-
carcinoma [24], breast carcinoma [26,27], and pan-
creatic adenocarcinoma [25]. To the best of our
knowledge, this marker has not been presented for
lung cancer.
Previous studies of MVD as a potential predictive
marker have given conflicting results [17,18,48]. A
recent review on anti-angiogenic therapies by Bugyik
et al proposes that the focus should be on patients
where primary tumours have endothelial proliferation
[49]. We found that proliferating vessels, expressed
as VPI, have a stronger impact on prognosis than
vessel density itself, and we propose that further
studies on the predictive impact of VPI are needed.
Comparing the frequencies of MVD to previous
studies on lung cancer is in part difficult due to the
range of methodologies for vessel counts
[12–14,23,30,50–52]. Our mean MVD/mm2 of 39.5
is somewhat low, and this could be due to our use of
Nestin as it is assumed to stain newly formed vessels
only. Previously, factor VIII, CD31, or CD34 have
been used to identify vessels [23,50,53,54], but as
these antibodies also stain existing vessels, they may
not reflect only the ongoing tumour-induced angio-
genesis. The lung is a highly vascularized organ,
especially around alveoli, and the use of pan-
endothelial markers is likely to give higher numbers
of microvessel density. By using Nestin and counting
the number of proliferating vessels, presented as VPI,
we hypothesize that this will provide a better esti-
mate of the neovascularization in lung tumours.
We found that the level of MVD was higher in pri-
mary tumours compared with paired metastatic
lesions. Differences in vascularity between primary
Figure 2. (A) Comparison of LCSS between adenocarcinoma
cases according to low or high VPI (by upper quartile; 4.4%;
Kaplan-Meier method). Numbers in brackets indicate events and
total number of cases in each subgroup. (B) Comparison of time
to recurrence between adenocarcinoma cases according to low
or high VPI (by upper quartile; 4.4%; Kaplan-Meier method).
Numbers in brackets indicate events and total number of cases
in each subgroup.
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tumours and metastatic lesions have been previously
reported for NSCLC [39], as well as for other
tumours [55–58], with the main result being that met-
astatic lesions had lower MVD than primary tumours.
The reasons for reduced MVD in metastatic lesions
could be that aggressive tumour cells are less
dependent on angiogenesis to form lesions at a dis-
tant site. There are reports of metastatic tumour cells
exploiting existing vessels for nutrient supply, by a
mechanism called vascular co-option [59]. This could
in part explain the lower microvascular density and
also the low vascular proliferation that we observed
in the metastatic lesions.
We are aware of limitations to our study in that
we used a retrospective cohort. However, our series
consists of tumour specimens from one institution
where the treatment of AC did not change much dur-
ing the study period. Of note, no patients received
anti-angiogenic treatment or tyrosine kinase inhibi-
tors. We have included all patients surgically treated
for lung AC in our county and in the time period,
and our cohort is considered to be representative for
the population. As to the possibility of sampling bias,
we acknowledge that the metastatic tissues used in
this study are biopsies and not surgical specimens,
and this may potentially account for some of the dis-
crepancies between vascular density in primary and
metastatic lesions.
As this is an early biomarker study, we have not
assessed vascular proliferation by the use of an image
analysis system. We are aware of the potential bene-
fits of such a method with increased standardization.
Still, a subjective evaluation by trained and experi-
enced personnel would be necessary to determine the
areas of interest, and to exclude parts of the tumour
that should not be included for assessment, such as
areas close to necrotic tissue and within tumour
scars. Also, most markers for endothelial cells (factor
VIII, CD 31, Nestin) stain other cells (fibroblasts,
nerves, tumour cells), and careful separation of these
cells would be needed. An automated counting sys-
tem should thus be thoroughly calibrated regarding
these measures, and could then possibly improve
inter-observer variability and also reduce the labour-
intensive task of counting MVD manually.
We also acknowledge that since this is the first study
showing a potential prognostic value of VPI in lung can-
cer, this marker should be validated in a similar and
independent cohort of surgically resected NSCLC.
The potential clinical implications of our findings
could be to use this angiogenesis marker in patient
stratification for closer follow-up after surgery. Also,
there is a possibility for using VPI as a tool for pre-
diction of response to anti-angiogenic treatment,
although this has not been the focus of our present
study. Currently, there is no validated predictor for
anti-angiogenic therapy, and this has been raised as
one of the problems concerning lack of improvement
in overall survival for the majority of patients [60].
The other problem is the toxicity linked to angiogen-
esis inhibitors, which could possibly be reduced if
drugs are given to patients most likely to benefit
from the treatment [61].
In this cohort of lung AC, we find that the novel
angiogenesis marker Nestin-Ki67, given as a VPI,
was associated with aggressive tumour features, such
as BVI and tumour necrosis and, independently, with
decreased LCSS. This marker should be explored fur-
ther in separate cohorts, including those that include
patients who have received anti-angiogenesis therapy.
Table 2. Univariate and multivariate analysis (by Cox’ proportional hazards method) of lung cancer specific survival for VPI (cut-off by
upper quartile) and other known prognostic factors in lung AC (n 5 210)
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Histological grade Absent 1.0 1.0
Present 1.6 (1.10–2.46) 0.017 1.2 (0.76–1.84) ns
BVI Absent 1.0 1.0
Present 2.2 (1.42–3.27) <0.001 1.3 (0.84–2.05) ns
LVI Absent 1.0 1.0
Present 2.7 (1.79–4.15) <0.001 1.8 (1.10–2.77) 0.017
Tumour necrosis Absent 1.0 1.0
Present 2.2 (1.39–3.32) 0.001 1.5 (0.92–2.40) ns
VPI* Low 1.0 1.0
High 1.7 (1.08–2.60) 0.022 1.7 (1.04–2.68) 0.033
Tumour stage I 1.0 1.0
II–IV 4.3 (2.63–7.18) <0.001 3.1 (1.78–5.38) <0.001
HR, hazard ratio; CI, confidence interval; VPI, vascular proliferation index; BVI, blood vessel invasion; LVI, lymph vessel invasion; ns, non-significant
(P value> 0.05).
*By upper quartile, 4.4%.
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